177,924 Shares in Inotiv, Inc. (NASDAQ:NOTV) Bought by Marshall Wace LLP

Marshall Wace LLP bought a new position in Inotiv, Inc. (NASDAQ:NOTV - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 177,924 shares of the company's stock, valued at approximately $737,000. Marshall Wace LLP owned approximately 0.68% of Inotiv at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Bay Colony Advisory Group Inc d b a Bay Colony Advisors purchased a new stake in Inotiv during the fourth quarter valued at about $60,000. Virtu Financial LLC bought a new position in shares of Inotiv in the fourth quarter worth $76,000. LPL Financial LLC purchased a new stake in shares of Inotiv in the fourth quarter worth $136,000. AlphaCentric Advisors LLC bought a new stake in Inotiv during the fourth quarter valued at $163,000. Finally, American Century Companies Inc. purchased a new position in Inotiv during the fourth quarter worth about $163,000. Hedge funds and other institutional investors own 18.17% of the company's stock.

Inotiv Price Performance

Shares of NASDAQ:NOTV traded up $0.23 on Wednesday, hitting $1.99. The company's stock had a trading volume of 652,245 shares, compared to its average volume of 561,660. The company has a market capitalization of $67.03 million, a PE ratio of -0.43 and a beta of 4.03. The company has a debt-to-equity ratio of 2.31, a current ratio of 1.57 and a quick ratio of 1.28. The company has a 50-day simple moving average of $2.31 and a 200 day simple moving average of $3.25. Inotiv, Inc. has a 1 year low of $1.15 and a 1 year high of $6.48.

Inotiv (NASDAQ:NOTV - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported ($0.18) EPS for the quarter, topping analysts' consensus estimates of ($0.23) by $0.05. Inotiv had a negative net margin of 25.40% and a negative return on equity of 15.41%. Sell-side analysts forecast that Inotiv, Inc. will post -0.79 EPS for the current fiscal year.

Insider Activity at Inotiv

In other news, CEO Robert Jr. Leasure sold 73,617 shares of the company's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $3.82, for a total value of $281,216.94. Following the completion of the transaction, the chief executive officer now directly owns 956,592 shares in the company, valued at approximately $3,654,181.44. This represents a 7.15 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold a total of 81,439 shares of company stock valued at $312,475 over the last 90 days. 7.80% of the stock is owned by insiders.

Inotiv Company Profile

Inotiv, Inc provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries. It operates through two segment: Discovery and Safety Assessment (DSA), and Research Models and Services (RMS). The DMS segment manufactured scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the Company's BASi product line.